Tag: Cguard

InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent

Peripheral/Endo by 0 comments

TEL AVIV, Israel, Jan. 24, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the presentation of […]

Continue Reading →

InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany

Peripheral/Endo by 0 comments

TEL AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured […]

Continue Reading →

InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

Neuro Peripheral/Endo by 0 comments

TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several […]

Continue Reading →

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

Neuro by 0 comments

TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that preliminary cumulative […]

Continue Reading →
1 2 3